Biomarkers in multiple sclerosis

Disease Markers

Volumn 22, Issue 4, 2006, Pages 183-185

  Martin, Roland ^a   Bielekova, Bibiana ^b   Hohlfeld, Reinhard ^c   Utz, Ursula ^d  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF CINCINNATI   (United States)

^c MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; GLATIRAMER; MITOXANTRONE;

CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DNA MICROARRAY; GENETICS; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RELAPSE; REMISSION;

EID: 33751100413     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/508354     Document Type: Conference Paper

References (5)

1. NIH-FDA Conference: Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Abstracts, Dis Markers 14(4) (1998), 187-334.
2. B. Bielekova and R. Martin, Development of biomarkers in multiple sclerosis, Brain 127(Pt 7) (2004), 1463-1478.
3. E. Floyd and T.M. McShane, Development and Use of Biomarkers in Oncology Drug Development, Toxicol Pathol 32(Supplement 1) (2004), 106-115.
4. L.J. Lesko and A.J. Atkinson, Jr., Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies, Annu Rev Pharmacol Toxicol 41 (2001), 347-366.
5. C. Lucchinetti, W. Bruck et al., Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination, Ann Neurol 47(6) (2000), 707-717.